# Deep Origin says BioAge validated computational drug candidates in laboratory tests

_Published Wednesday, October 14, 2026 at 11:19 AM EDT · AI · Latest · Tier 2 — Notable_

![Deep Origin says BioAge validated computational drug candidates in laboratory tests — Primary](https://s.yimg.com/cv/apiv2/cv/apiv2/social/images/yahoo-finance-default-logo.png)

Deep Origin announced a multi-target drug discovery collaboration with BioAge Labs and said BioAge's laboratory had validated small-molecule hits against the partnership's first target. The platform delivered multiple structurally distinct hits in less than three months, and BioAge is moving that target into optimization of the initial compounds.

Deep Origin combines AI and physics-based models to predict how molecules bind to proteins, filtering candidates against BioAge's medicinal chemistry criteria before laboratory testing. BioAge handles functional validation, optimization and clinical development. Deep Origin is eligible for success-based milestone payments; work to validate hits against additional targets continues.

## Sources

- [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/deep-origin-announces-multi-target-120000257.html)

---
Canonical: https://techandbusiness.org/newswire/CUvoiDHhRMU5rjLSJR7feO
Published: 2026-10-14T15:19:06.143Z
Story chronology: 2026-10-14T12:00:00.000Z
Retrieved: 2026-10-14T18:03:34.132Z
Publisher: Tech & Business (techandbusiness.org)